Changes in HCT and Hgb levels
| Longitudinal studies | ||||||||
| Author (year) | Participants (N) | Measure (units) | Baseline mean±SD (95% CI) | Follow-up mean±SD (95% CI) | Number of months | % Change | P | T (nmol/L) Base-post GAHT |
| TW | ||||||||
| Wierckx (2014) | 40 (oral oestrogen) 12 (transdermal oestrogen) | HCT (%) | 45±2.5 45.5±1.7 | 42±5.7 42.2±2.3 | 12 12 | −7.0 −4.6 | <0.01 <0.001 | 18.0–0.4 19.7–0.5 |
| Auer et al (2016)46 | 20 | HCT (%) | 45.2±2.7 | 42.7±1.8 | 12 | −5.5 | <0.01 | 17.5–1.9 |
| Jarin et al (2017)39 | 13 | HCT (%) | 43.8 | 42.3 | 6 | −3.4 | >0.05 | 13.6–6.9 |
| Vita et al (2018)48 | 21 | HCT (%) | 44.8±2.9 | 40.1±2.6 | 6–30 | −10.5 | <0.001 | 20.5–1.1 |
| Defreyne et al (2018)19 | 239 | HCT (%) | 45.0±2.5 (44.9–45.5) | 41.0±3.1 (40.9– 41.7) 41.1±3.2 (40.5– 41.2) 40.7±3.2 (40.0– 40.8) | 3 6 24 | −8.9 −8.7 −9.6 | <0.001 <0.001 <0.001 | 17.4–0.7 17.4–0.6 17.4–0.6 |
| Tack et al (2017)47 | 21 | HCT (%) | 43.8±1.9 | 39.9±2.2 | 12–31 | −8.9 | <0.001 | 15.2–8.8 |
| Gooren and Bunck (2004)43 | 19 | Hgb (mmol/L) | 9.3±0.7 | 8.0±0.7 8.1±0.6 | 12 36 | −14.0 −12.9 | <0.001 <0.001 | 21.5–1.0 21.5–0.9 |
| Olson-Kennedy et al (2018)49 | 23 | Hgb (g/dL) | 153±11 | 140±12 | 12 | −8.3 | <0.001 | 14.8–5.9 |
| Wiik (2020)16 | 9 10 | Hgb (g/L) | 148.3±10.1 150.3±9.1 | 132.7±9.1 133.3±9.0 | 4 12 | −10.5 −11.7 | <0.001 <0.001 | 18.0–0.5 18.0–0.5 |
| Cross-sectional studies | |||||||||||
| Author (year) | Participants (N) | Measure (units) | TW mean±SD or (range) | Control mean±SD or (range) | Number of months | % Difference | P | T (nmol/L) TW | |||
| TW | CM | CW | HNTW | ||||||||
| Lapauw et al (2008)54 | 23 | 46 | HCT (%) | 41.2±2.3 | 45.3±2.3 | >48 | −9.1 | <0.001 | 1.1 | ||
| SoRelle et al (2019)52 | 105 | 73 | HCT (%) | (35.9– 48.7) | (39.0– 50.6) | >6 | – | d=1.0 | 1.9 | ||
| Greene et al (2019)18 | 93 | HCT (%) | (35–47) | (35.5– 46) CW | >12 | – | >0.05 | 1.4 | |||
| Roberts et al (2014)53 | 55 | 20 | 20 | HCT (%) | (34.6–43.7) | (38.4– 45.7) CM (34.4– 41.9) CW | >6 | – – | <0.01 >0.05 | ||
| Jain (2019) | 182 (oestrogen) 95 (oestrogen +progesterone) | 92 | HCT (%) | 42.5 40.9 | 45.9±2.0 | >3 | −7.4 −10.9 | <0.05 <0.05 | |||
| Sharula (2012)37 | 129 | 22 | HCT (%) | 40.2±3.1 | 44.4±2.4 | >3 | −9.5 | <0.001 | 2.5 | ||
CM, cismen; CW, ciswomen; HCT, haematocrit; Hgb, haemoglobin; HNTW, hormone-naive transwomen; TW, transwomen.